Bronchitis: Clinical Trials

170 trials for Bronchitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

170 completed. 170 Phase 2, 36 Phase 1, 15 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2170Completed 170
Phase 136Completed 36
Phase 315Completed 15

Follow Bronchitis: new trials by email Literature Review of Bronchitis trials Research Report on Bronchitis

Trials (filtered) newest first · largest first

All 170 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
ALC-2203-1, ALC-2203-2, ALC-2203-AC - Acute Bronchitis
Phase 2CompletedKorea Arlico Pharm. Co., Ltd1692025-04-232025-12-24
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
RSP-1502, Tobramycin inhalation solution - Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic
Phase 1 / Phase 2CompletedRespirion Pharmaceuticals Pty Ltd712024-04-012026-06-25
Efficacy of Vitamin D Supplementation for Children With Bronchiolitis
Vitamin D3 - Bronchiolitis
Phase 2 / Phase 3CompletedSohag University1462023-04-012024-10-29
Nebulised 3% Hypertonic Saline in Infants With Acute Bronchiolitis
3% Sodium Chloride, Standard care - Acute Bronchiolitis
Phase 2 / Phase 3CompletedCan Tho University of Medicine and Pharmacy1402022-06-012024-08-16
Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes
E-Cigarette, Financial Incentives - Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Phase 2CompletedUniversity of Vermont212022-04-282024-02-08
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Belumosudil 200 mg QD, Belumosudil 200 mg BID, Belumosudil 400 mg QD - Chronic Graft-versus-host-disease
Phase 2CompletedKadmon, a Sanofi Company232022-02-232025-05-02
Bacterial Lysate In Preventing Asthma
Bacterial Lysate - Respiratory Tract Infections, Pediatric Respiratory Diseases
Phase 2CompletedQueen Mary University of London1732022-01-122026-05-19
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
asciminib, best available treatment - Leukemia, Chronic Myelogenous
Phase 2CompletedNovartis Pharmaceuticals842021-12-062025-04-18
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
Ibrutinib, ECG, PFT's - Chronic GVHD
Phase 2CompletedNational Cancer Institute (NCI)102021-05-102026-01-23
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
BN101 - GVHD, Chronic
Phase 2CompletedBioNova Pharmaceuticals (Shanghai) LTD.302021-04-272024-01-17
Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease
Allogeneic platelet lysate eye drops - Ocular Graft-versus-host Disease
Phase 2CompletedSt. Petersburg State Pavlov Medical University382021-04-012024-12-04
Dexamethasone Solution and Dexamethasone in Mucolox™
dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™ - Oral Lichen Planus, Mucous Membrane Pemphigoid
Phase 2CompletedUniversity of California, San Francisco292020-12-262023-12-15
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
Tozorakimab, Placebo - Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
Phase 2CompletedAstraZeneca1372020-12-142025-02-27
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
dupilumab, placebo - Chronic Sinusitis
Phase 2CompletedJohns Hopkins University332020-10-152025-11-03
Hp129 Xenon Imaging and BOS in Lung Transplantation
Hp 129Xenon - Bronchiolitis Obliterans
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati32020-09-092026-09-18
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
INC424 - Graft vs Host Disease
Phase 2CompletedNovartis Pharmaceuticals462020-05-202025-12-11
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
HB-adMSCs - Traumatic Brain Injury
Phase 1 / Phase 2CompletedHope Biosciences LLC242020-01-012026-01-15
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Acalabrutinib 2x100 MG Oral Capsule + alloSCT - Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease
Phase 2CompletedPolish Lymphoma Research Group292019-08-192025-01-16
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Nintedanib - Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO)
Phase 2CompletedUniversity Hospital, Basel, Switzerland202019-03-202026-10-27
PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT
PT-CY-FK +/-ATG - GVHD, Acute
Phase 2CompletedShanghai Jiao Tong University School of Medicine232019-01-012021-05-21

Showing 20 of 170. Sign in to see all of them.

Narrower conditions

Bronchiolitis Obliterans Syndrome (107)  ·  Pulmonary Disease, Chronic Obstructive (33)  ·  Bronchitis, Chronic (30)  ·  Bronchiolitis (17)  ·  Emphysema (16)  ·  Graft vs Host Disease (15)  ·  Bronchiolitis Obliterans (12)  ·  Leukemia (12)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (9)  ·  Lymphoma, Follicular (6)  ·  Hepatitis C (4)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4)  ·  Lung Diseases (4)  ·  Neoplasms (4)

Broader conditions

Bronchial Diseases (169)  ·  Respiratory Tract Diseases (169)  ·  Lung Diseases, Obstructive (167)  ·  Lung Diseases (166)  ·  Bronchiolitis (117)  ·  Immune System Diseases (110)  ·  Organizing Pneumonia (108)  ·  Bronchiolitis Obliterans (105)  ·  Graft vs Host Disease (94)  ·  Pathological Conditions, Signs and Symptoms (80)  ·  Infections (68)  ·  Pathologic Processes (64)  ·  Disease Attributes (59)  ·  Chronic Disease (57)

Interventions

Formoterol Fumarate (7)  ·  montelukast (5)  ·  N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide (4)  ·  Ribavirin (4)  ·  Rituximab (4)  ·  aclidinium bromide (4)  ·  ibrutinib (4)  ·  Azithromycin (3)  ·  Cholecalciferol (3)  ·  Fluticasone (3)  ·  Prednisone (3)  ·  Saline Solution (3)  ·  Saline Solution, Hypertonic (3)  ·  Sirolimus (3)  ·  Sodium Chloride (3)

Sponsors

AstraZeneca (9)  ·  Novartis Pharmaceuticals (6)  ·  GlaxoSmithKline (5)  ·  Fred Hutchinson Cancer Center (4)  ·  National Cancer Institute (NCI) (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Dana-Farber Cancer Institute (3)  ·  Beth Israel Deaconess Medical Center (2)  ·  Dey (2)  ·  Eli Lilly and Company (2)  ·  Genta Incorporated (2)  ·  Gilead Sciences (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Hanlim Pharm. Co., Ltd. (2)  ·  MetrioPharm AG (2)

Countries

United States (91)  ·  Canada (19)  ·  Germany (18)  ·  United Kingdom (15)  ·  Spain (13)  ·  Poland (11)  ·  Russia (10)  ·  South Korea (10)  ·  France (9)  ·  Italy (9)  ·  Australia (8)  ·  Czechia (7)  ·  Japan (6)  ·  Netherlands (6)  ·  Taiwan (6)

Top investigators

Stephanie Lee (5)  ·  Esther Garcia, MD (4)  ·  Ahmet Tutuncu, MD, PhD (2)  ·  Nicole J Gormley, M.D. (2)  ·  Radmila Razlog, M.TechHom (2)  ·  Steven Z Pavletic, M.D. (2)  ·  Alan H Lau, Pharm.D. (1)  ·  Aldo T Iacono, MD (1)  ·  Alessandro Villa, DDS, PhD, MPH (1)  ·  Allyson Gage, PhD (1)

Results publications

PMID 24432712, PMID 25287629, PMID 34773261, PMID 36440464, PMID 16186597, PMID 18219306, PMID 18502835, PMID 19017883, PMID 19745067, PMID 19750190, PMID 20007923, PMID 21039672, PMID 21073773, PMID 21937568, PMID 22155140, PMID 22197578, PMID 22292600, PMID 22455413, PMID 22458939, PMID 22772084, PMID 23172272, PMID 23861248, PMID 23903014, PMID 24139233, PMID 24382580, PMID 24393134, PMID 24400934, PMID 24410959, PMID 24484754, PMID 24862623, PMID 24928639, PMID 24995488, PMID 25168853, PMID 25242558, PMID 25243340, PMID 25261839, PMID 25265132, PMID 25693783, PMID 25835160, PMID 26043724, PMID 26189353, PMID 26286532, PMID 26475726, PMID 26945226, PMID 27102120, PMID 27724916, PMID 27977439, PMID 28286262, PMID 28924018, PMID 28987804

NIH funding

P30CA015704 (4), 2009 (3), 2014 (2), 2015 (2), 2017 (2), 2018 (2), 2005 (1), 2016 (1), R01AT005436 (1), R03NR009361 (1), R34HL127166 (1), R44HL073591 (1), U01AT001908 (1), U01HL069294 (1), U24CA076518 (1)